NCT07323095RecruitingPhase 2
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 8 Dec 2025
- Start date
- 2 Oct 2026
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Atom Therapeutics Co., Ltd
- Diseases
- Chronic kidney disease
- NCT number
- NCT07323095
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From 2 Oct 2026 to the primary completion date, 31 Oct 2027
- 10 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who have participated in another clinical study during the screening period are within 30 days of the last dose of the study drug in another study
Other illness
- History of renal transplantation
- Subjects with mental disorders who are unable to communicate normally with the investigator
Lab values
- Liver function abnormality: aspartate aminotransferase or alanine aminotransferase, or alkaline phosphatase \> 3 times the upper limit of normal value (ULN)
Other
- The 24-hour urinary protein ≥ 3.5 g/day
- The investigator judged that the subject was not suitable for participation in this study
Who the study is looking for
- Male or female aged 18-75 years , who voluntarily participate in this clinical trial, understand and comply with the procedures stipulated in this study
- Patients who have been diagnosed with CKD based on Clinical Practice Guideline
- During screening, body mass index (BMI) was ≥18.0 and ≤ 40.0 kg/m2
- The sUA levels \> 420 μmol/L (7.0 mg/dL)
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Paratus Clinical Research Brisbane Coordinator of this site? Confirm its status | Brisbane | Australia | Recruiting |
| Renal Research Gosford Pty Ltd Coordinator of this site? Confirm its status | Gosford | Australia | Not yet recruiting |
| Genesis Research Services Coordinator of this site? Confirm its status | Newcastle | Australia | Recruiting |
| Beijing Tsinghua Changgung Hospital Coordinator of this site? Confirm its status | Beijing | China | Not yet recruiting |
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Not yet recruiting |
| Xuanwu Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Not yet recruiting |
| Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Not yet recruiting |
| Zhejiang Provincial People's Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Not yet recruiting |
| Jiangsu Province Hospital Coordinator of this site? Confirm its status | Nanjing | China | Not yet recruiting |
| Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.